Dice Therapeutics Stock Price, News & Analysis
Company Description
Dice Therapeutics (NASDAQ: DICE) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $2.3B.
DICE stock has declined 100.0% over the past year.
This page provides a comprehensive overview of DICE stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Dice Therapeutics (DICE) stock. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $2.3B, DICE is classified as a mid-cap stock with approximately 47.8M shares outstanding.
Latest News
Dice Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include acquisition, conferences, earnings. View all DICE news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
DICE Company Profile & Sector Positioning
Dice Therapeutics (DICE) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing DICE often look at related companies in the same sector, including Ocular Therapeut (OCUL), Tarsus Pharmaceuticals, Inc. (TARS), Amicus Therapeut (FOLD), Liquidia Corporation (LQDA), and Travere Therapeutics Inc (TVTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate DICE's relative position within its industry.